Goodpasture syndrome overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:
{{CMG}}{{APM}};{{AE}}{{KW}}{{Akshun}}
{{CMG}}{{APM}};{{AE}}{{KW}}{{Akshun}}
==Overview==
==Overview==
'''Goodpasture’s disease''' is a rare condition characterised by rapid destruction of the [[kidney]]s and the [[lung]]s. It is a type type II hypersensitivity reaction in which autoantibodies are produced against glomerular and alveolar basement membrane. The term Goodpasture syndrome is named after American physician Dr. [[Ernest William Goodpasture]]. There are no known direct causes for Goodpasture syndrome. However, Goodpasture syndrome must be differentiated from other diseases that cause rapid progressive glomerulonephritis and pulmonary hemorrhage. The prevalence of Goodpasture syndrome worldwide is an estimated 1 per million individuals, with high prevalence in Caucasians. Common risk factors in the development of Goodpasture syndrome may be occupational, environmental, genetic, and viral. Symptoms of Goodpasture syndrome include, malaise, pyrexia and chills and arthralgia, fatigue, lethargy, pallor, and anorexia. Laboratory findings consistent with the diagnosis of Goodpasture syndrome include presence of autoantibodies such as  anti-glomerular basement membrane antibodies. The mainstay of therapy for Goodpasture syndrome consist of corticosteroids, cyclophosphamide and plasmapheresis.
'''Goodpasture’s disease''' is a rare condition characterised by rapid destruction of the [[kidney]]s and the [[lung]]s. It is a type [[type II hypersensitivity]] reaction in which [[autoantibodies]] are produced against [[glomerular]] [[basement membrane]] (GBM) and [[alveolar]] [[basement membrane]]. The term Goodpasture syndrome is named after American physician Dr. [[Ernest William Goodpasture]]. There are no known direct causes for Goodpasture syndrome. However, Goodpasture syndrome must be differentiated from other diseases that cause rapid progressive [[glomerulonephritis]] and [[pulmonary hemorrhage]]. The [[prevalence]] of Goodpasture syndrome worldwide is an estimated 1 case per million individuals, with high [[prevalence]] in Caucasians. Common risk factors in the development of Goodpasture syndrome may be occupational, environmental, genetic, and viral. Symptoms of Goodpasture syndrome include, [[malaise]], [[pyrexia]] and [[chills]] and [[arthralgia]], [[fatigue]], [[lethargy]], [[pallor]], and [[anorexia]]. Laboratory findings consistent with the diagnosis of Goodpasture syndrome include presence of [[autoantibodies]] such as  [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane antibodies]]. The mainstay of therapy for Goodpasture syndrome consist of [[corticosteroids]], [[cyclophosphamide]] and [[plasmapheresis]].


==Historical Perspective==
==Historical Perspective==
Goodpasture syndrome was first discovered by Dr.[[Ernest William Goodpasture]], an American pathologist and physician, who studied the influenza pandemic in 1919, described a fatal disease that was associated with glomerulonephritis and pulmonary hemorrhage.
Goodpasture syndrome was first discovered by Dr.[[Ernest William Goodpasture]], an American [[pathologist]] and physician, who studied the [[influenza]] pandemic in 1919, described a fatal disease that was associated with [[glomerulonephritis]] and [[pulmonary hemorrhage]].


==Classification==
==Classification==
Line 20: Line 20:


==Pathophysiology==
==Pathophysiology==
The pathogenesis of Goodpasture syndrome includes the presence of auto-antibodies directed against the glomerular or alveolar basement membrane. As with many autoimmune conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a type II hypersensitivity reaction to Goodpasture’s antigens on the cells of the glomeruli of the kidneys and the pulmonary alveoli, specifically the basement membrane's (including a-3 chain of type IV collagen), whereby the immune system wrongly recognizes these cells as foreign and attacks and destroys them, as it would an invading pathogen.
The [[pathogenesis]] of Goodpasture syndrome includes the presence of [[Autoantibody|autoantibodies]] directed against the [[glomerular]] or [[alveolar]] [[Basement membrane|basement membrane.]] As with many [[autoimmune]] conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a [[type II hypersensitivity]] reaction to Goodpasture’s [[antigens]] on the [[cells]] of the [[glomeruli]] of the [[kidneys]] and the [[Pulmonary alveolus|pulmonary alveoli]], specifically the [[basement membrane]]'s (including a-3 chain of [[type IV collagen]]), whereby the [[immune system]] wrongly recognizes these cells as foreign and attacks and destroys them, as it would an invading pathogen. The target [[antigen]] that has the strongest pathogenic effect on [[Goodpasture disease|anti-GBM disease]] is the non-collagenous 1 domain of alpha-3 [[type IV collagen]]. There is strong correlation of [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane]] disease with allele HLA DRB1-1501. This [[allele]] is associated in causing [[renal injury]]. On gross pathology, Goodpasture syndrome with lung involvement may present with diffuse [[pulmonary hemorrhage]]. On microscopic [[histopathological]] analysis, early focal proliferative changes that display [[necrosis]] and crescent formation with an inflamed [[interstitial]] are seen. Under direct immunofluorescence,  linear [[immunoglobulin G]] deposits are found encompassing the [[glomerular basement membrane]] and at times the distal [[tubular]] portion of the [[Basement membrane|basement membrane.]] Other diagnostic studies for Goodpasture syndrome include renal [[biopsy]].
The target antigen that has the strongest pathogenic effect on anti-GBM disease is the non-collagenous 1 domain of alpha-3 type IV collagen. There is strong correlation of anti-glomerular basement membrane disease with allele HLA DRB1-1501.This allele is associated in causing renal injury. On gross pathology, Goodpasture syndrome with lung involvement may present with diffuse pulmonary hemorrhage. On microscopic histopathological analysis, early focal proliferative changes that display necrosis and crescent formation with an inflamed interstitial are seen. Under direct immunofluorescence,  linear immunoglobulin G deposits are found encompassing the glomerular basement membrane and at times the distal tubular portion of the basement membrane.  Other diagnostic studies for Goodpasture syndrome include renal biopsy.


==Causes==
==Causes==
There are no known direct causes for Goodpasture syndrome. Common risk factors for Goodpasture syndrome are viral or bacterial infections and certain environmental and behavioral risk factors such as smoking, hydrocarbons, formaldehyde and cocaine use.
There are no known direct causes for Goodpasture syndrome. Common risk factors for Goodpasture syndrome are [[viral]] or [[bacterial]] [[infections]] and certain environmental and behavioral risk factors such as [[smoking]], [[hydrocarbons]], [[formaldehyde]] and [[cocaine]] use.


==Differentiating Goodpasture syndrome from Other Diseases==
==Differentiating Goodpasture syndrome from Other Diseases==
Goodpasture syndrome must be differentiated from other diseases that cause rapid progressive glomerulonephritis and pulmonary hemorrhage. ANCA associated vasculitis, are disorders that affect the renal and pulmonary system, must be differentiated from Goodpasture syndrome.
Goodpasture syndrome must be differentiated from other diseases that cause rapid progressive [[glomerulonephritis]] and [[pulmonary hemorrhage]]. [[ANCA]] associated [[vasculitis]], are disorders that affect the renal and pulmonary system, must be differentiated from Goodpasture syndrome.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The prevalence of Goodpasture syndrome worldwide is an estimated 1 per million individuals, with high prevalence in Caucasians. The peak incidence of the disease occurs between the ages of 20 and 30 and again at 60 and 70. Goodpasture syndrome affects men and women equally.
The [[prevalence]] of Goodpasture syndrome worldwide is an estimated 1 case per million individuals, with high [[prevalence]] in Caucasians. The peak [[incidence]] of the disease occurs between the ages of 20 and 30 and again at 60 and 70. Goodpasture syndrome affects men and women equally.


==Risk Factors==
==Risk Factors==
Common risk factors in the development of Goodpasture syndrome may be occupational, environmental, genetic, and viral. However, we don't known what causes the antibodies to form. However, we don't known what causes the antibodies to form.
Common risk factors in the development of Goodpasture syndrome may be occupational, environmental, [[genetic]], and [[viral]]. However, we don't known what causes the antibodies to form.  


==Screening==
==Screening==
There is insufficient evidence to recommend routine screening for Goodpasture syndrome.
There is insufficient evidence to recommend routine [[Screening (medicine)|screening]] for Goodpasture syndrome.


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
If left untreated, Goodpasture syndrome can progress to end stage renal disease and pulmonary failure. Complications of Goodpasture syndrome include, infections, alveolar hemorrhage, end stage renal disease, and pulmonary failure. The prognosis of Goodpasture syndrome is variable, as it depends upon the diagnosis, start of treatment and the level of serum creatinine.
If left untreated, Goodpasture syndrome can progress to [[end stage renal disease]] and [[pulmonary failure]]. Complications of Goodpasture syndrome include, [[infections]], [[alveolar]] hemorrhage, [[end stage renal disease]], and [[pulmonary failure]]. The prognosis of Goodpasture syndrome is variable, as it depends upon the [[diagnosis]], start of treatment and the level of [[serum creatinine]].


==Diagnosis==
==Diagnosis==
===History and Symptoms===
===History and Symptoms===
Obtaining a complete history is an important aspect of making a diagnosis of Goodpasture syndrome, as it can provide insight into cause, precipitating factors, and associated underlying conditions. Symptoms may develop acutely or rapidly affecting the renal and pulmonary system. Symptoms of Goodpasture syndrome include, malaise, pyrexia and chills and arthralgia, fatigue, lethargy, pallor, and anorexia.
Obtaining a complete history is an important aspect of making a diagnosis of Goodpasture syndrome, as it can provide insight into cause, precipitating factors, and associated underlying conditions. Symptoms may develop acutely or rapidly affecting the [[renal]] and [[pulmonary]] system. Symptoms of Goodpasture syndrome include, [[malaise]], [[pyrexia]] and [[chills]] and [[arthralgia]], [[fatigue]], [[lethargy]], [[pallor]], and [[anorexia]].


===Physical Examination===
===Physical Examination===
A complete medical history and comprehensive renal and pulmonary exam must be preformed to help identify and properly diagnose Goodpasture syndrome.The presence of tachypnea, inspiratory crackles, edema and hypertension on physical examination are suggestive of presence of renal and pulmonary disorders such as Goodpasture syndrome.
A complete medical history and comprehensive [[renal]] and [[pulmonary]] exam must be performed to help identify and properly diagnose Goodpasture syndrome.The presence of [[tachypnea]], inspiratory [[crackles]], [[edema]] and [[hypertension]] on physical examination are suggestive of presence of [[renal]] and [[pulmonary]] disorders such as Goodpasture syndrome.


===Laboratory Findings===
===Laboratory Findings===
Laboratory findings consistent with the diagnosis of Goodpasture syndrome include presence of auto-antibodies such as anti-glomerular basement membrane antibodies. Other findings associated with pulmonary and renal injury include elevated blood urea nitrogen, low-grade proteinuria, gross or microscopic hematuria, and red cell casts.
Laboratory findings consistent with the diagnosis of Goodpasture syndrome include presence of [[autoantibodies]] such as [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane antibodies]]. Other findings associated with [[pulmonary]] and [[renal]] injury include elevated [[blood urea nitrogen]], low-grade [[proteinuria]], gross or [[microscopic hematuria]], and red cell casts.


===X-ray===
===X-ray===
On Chest X-ray, Goodpasture syndrome is characterized by parenchymal consolidations that are most often present in both lungs, perihilar, and bibasilar. When pulmonary hemorrhage is recurrent an interstitial pattern is observed.
On [[chest X-ray]], Goodpasture syndrome is characterized by [[parenchymal]] consolidations that are most often present in both [[lungs]], perihilar, and bibasilar. When pulmonary hemorrhage is recurrent an interstitial pattern is observed.


===Echocardiography and Ultrasound===
===Echocardiography and Ultrasound===
There are no echocardiography/ultrasound findings associated with Goodpasture syndrome.
There are no [[echocardiography]]/[[ultrasound]] findings associated with Goodpasture syndrome.


===CT scan===
===CT scan===
CT scan of the thorax may be helpful in the diagnosis of Goodpasture syndrome. Findings on CT scan suggestive of Goodpasture syndrome include parenchymal consolidation, ground glass appearance that may progress to reticular pattern and interlobular septal thickening in later stage of diesease.
[[CT scan]] of the [[thorax]] may be helpful in the diagnosis of Goodpasture syndrome. Findings on [[CT scan]] suggestive of Goodpasture syndrome include [[parenchymal]] [[Consolidation (medicine)|consolidation]], ground glass appearance that may progress to reticular pattern and interlobular septal thickening in later stage of disease.


===Other Diagnostic Studies===
===Other Diagnostic Studies===
Other diagnostic studies for Goodpasture syndrome include renal biopsy. In patients with inconclusive lab and imaging findings, renal biopsy remains the gold standard in establishing the presence of Goodpasture syndrome. A renal biopsy can also identify the severity of disease and guide medical therapy.
Other diagnostic studies for Goodpasture syndrome include renal [[biopsy]]. In patients with inconclusive lab and imaging findings, renal [[biopsy]] remains the [[Gold standard (test)|gold standard]] in establishing the presence of Goodpasture syndrome. A renal [[biopsy]] can also identify the severity of disease and guide medical therapy.


==Treatment==
==Treatment==
===Medical Therapy===
===Medical Therapy===
Currently there is no cure for Goodpasture syndrome.The mainstay of therapy for Goodpasture syndrome consist of corticosteroids, cyclophosphamide and plasmapheresis.
Currently there is no cure for Goodpasture syndrome.The mainstay of therapy for Goodpasture syndrome consist of [[corticosteroids]], [[cyclophosphamide]] and [[plasmapheresis]].


===Surgery===
===Surgery===
Surgery is not the first-line treatment option for patients with Goodpasture syndrome. Renal transplantation is usually reserved for patients who present with undetectable circulating anti-glomerular basement antibodies in serum for 12 months and atleast 6 months after stopping the use of cytotoxic agents.
Surgery is not the first-line treatment option for patients with Goodpasture syndrome. [[Renal transplantation]] is usually reserved for patients who present with undetectable circulating [[Anti-glomerular basement membrane antibody|anti-glomerular basement antibodie]]<nowiki/>s in serum for 12 months and atleast 6 months after stopping the use of [[cytotoxic]] agents.


===Secondary Prevention===
===Secondary Prevention===
Effective measures for the secondary prevention of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys. Patients should be monitored regularly for renal function and those with severe dysfunction should have be referred for dialysis.
Effective measures for the [[secondary prevention]] of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of [[renal]] dysfunction as certain [[steroid]] and [[immunosuppressive]] therapy may have adverse effects on the [[kidneys]]. Patients should be monitored regularly for [[renal function]] and those with severe dysfunction should have be referred for [[dialysis]].


==References==
==References==

Revision as of 13:57, 1 May 2018

Title
https://https://www.youtube.com/watch?v=vAX2UMA8Oek%7C350}}

Goodpasture syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Goodpasture syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goodpasture syndrome overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Goodpasture syndrome overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goodpasture syndrome overview

CDC on Goodpasture syndrome overview

Goodpasture syndrome overview in the news

Blogs on Goodpasture syndrome overview

Directions to Hospitals Treating Goodpasture syndrome

Risk calculators and risk factors for Goodpasture syndrome overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3] Akshun Kalia M.B.B.S.[4]

Overview

Goodpasture’s disease is a rare condition characterised by rapid destruction of the kidneys and the lungs. It is a type type II hypersensitivity reaction in which autoantibodies are produced against glomerular basement membrane (GBM) and alveolar basement membrane. The term Goodpasture syndrome is named after American physician Dr. Ernest William Goodpasture. There are no known direct causes for Goodpasture syndrome. However, Goodpasture syndrome must be differentiated from other diseases that cause rapid progressive glomerulonephritis and pulmonary hemorrhage. The prevalence of Goodpasture syndrome worldwide is an estimated 1 case per million individuals, with high prevalence in Caucasians. Common risk factors in the development of Goodpasture syndrome may be occupational, environmental, genetic, and viral. Symptoms of Goodpasture syndrome include, malaise, pyrexia and chills and arthralgia, fatigue, lethargy, pallor, and anorexia. Laboratory findings consistent with the diagnosis of Goodpasture syndrome include presence of autoantibodies such as anti-glomerular basement membrane antibodies. The mainstay of therapy for Goodpasture syndrome consist of corticosteroids, cyclophosphamide and plasmapheresis.

Historical Perspective

Goodpasture syndrome was first discovered by Dr.Ernest William Goodpasture, an American pathologist and physician, who studied the influenza pandemic in 1919, described a fatal disease that was associated with glomerulonephritis and pulmonary hemorrhage.

Classification

There is no established system for the classification of Goodpasture syndrome.

Pathophysiology

The pathogenesis of Goodpasture syndrome includes the presence of autoantibodies directed against the glomerular or alveolar basement membrane. As with many autoimmune conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a type II hypersensitivity reaction to Goodpasture’s antigens on the cells of the glomeruli of the kidneys and the pulmonary alveoli, specifically the basement membrane's (including a-3 chain of type IV collagen), whereby the immune system wrongly recognizes these cells as foreign and attacks and destroys them, as it would an invading pathogen. The target antigen that has the strongest pathogenic effect on anti-GBM disease is the non-collagenous 1 domain of alpha-3 type IV collagen. There is strong correlation of anti-glomerular basement membrane disease with allele HLA DRB1-1501. This allele is associated in causing renal injury. On gross pathology, Goodpasture syndrome with lung involvement may present with diffuse pulmonary hemorrhage. On microscopic histopathological analysis, early focal proliferative changes that display necrosis and crescent formation with an inflamed interstitial are seen. Under direct immunofluorescence, linear immunoglobulin G deposits are found encompassing the glomerular basement membrane and at times the distal tubular portion of the basement membrane. Other diagnostic studies for Goodpasture syndrome include renal biopsy.

Causes

There are no known direct causes for Goodpasture syndrome. Common risk factors for Goodpasture syndrome are viral or bacterial infections and certain environmental and behavioral risk factors such as smoking, hydrocarbons, formaldehyde and cocaine use.

Differentiating Goodpasture syndrome from Other Diseases

Goodpasture syndrome must be differentiated from other diseases that cause rapid progressive glomerulonephritis and pulmonary hemorrhage. ANCA associated vasculitis, are disorders that affect the renal and pulmonary system, must be differentiated from Goodpasture syndrome.

Epidemiology and Demographics

The prevalence of Goodpasture syndrome worldwide is an estimated 1 case per million individuals, with high prevalence in Caucasians. The peak incidence of the disease occurs between the ages of 20 and 30 and again at 60 and 70. Goodpasture syndrome affects men and women equally.

Risk Factors

Common risk factors in the development of Goodpasture syndrome may be occupational, environmental, genetic, and viral. However, we don't known what causes the antibodies to form.

Screening

There is insufficient evidence to recommend routine screening for Goodpasture syndrome.

Natural History, Complications, and Prognosis

If left untreated, Goodpasture syndrome can progress to end stage renal disease and pulmonary failure. Complications of Goodpasture syndrome include, infections, alveolar hemorrhage, end stage renal disease, and pulmonary failure. The prognosis of Goodpasture syndrome is variable, as it depends upon the diagnosis, start of treatment and the level of serum creatinine.

Diagnosis

History and Symptoms

Obtaining a complete history is an important aspect of making a diagnosis of Goodpasture syndrome, as it can provide insight into cause, precipitating factors, and associated underlying conditions. Symptoms may develop acutely or rapidly affecting the renal and pulmonary system. Symptoms of Goodpasture syndrome include, malaise, pyrexia and chills and arthralgia, fatigue, lethargy, pallor, and anorexia.

Physical Examination

A complete medical history and comprehensive renal and pulmonary exam must be performed to help identify and properly diagnose Goodpasture syndrome.The presence of tachypnea, inspiratory crackles, edema and hypertension on physical examination are suggestive of presence of renal and pulmonary disorders such as Goodpasture syndrome.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Goodpasture syndrome include presence of autoantibodies such as anti-glomerular basement membrane antibodies. Other findings associated with pulmonary and renal injury include elevated blood urea nitrogen, low-grade proteinuria, gross or microscopic hematuria, and red cell casts.

X-ray

On chest X-ray, Goodpasture syndrome is characterized by parenchymal consolidations that are most often present in both lungs, perihilar, and bibasilar. When pulmonary hemorrhage is recurrent an interstitial pattern is observed.

Echocardiography and Ultrasound

There are no echocardiography/ultrasound findings associated with Goodpasture syndrome.

CT scan

CT scan of the thorax may be helpful in the diagnosis of Goodpasture syndrome. Findings on CT scan suggestive of Goodpasture syndrome include parenchymal consolidation, ground glass appearance that may progress to reticular pattern and interlobular septal thickening in later stage of disease.

Other Diagnostic Studies

Other diagnostic studies for Goodpasture syndrome include renal biopsy. In patients with inconclusive lab and imaging findings, renal biopsy remains the gold standard in establishing the presence of Goodpasture syndrome. A renal biopsy can also identify the severity of disease and guide medical therapy.

Treatment

Medical Therapy

Currently there is no cure for Goodpasture syndrome.The mainstay of therapy for Goodpasture syndrome consist of corticosteroids, cyclophosphamide and plasmapheresis.

Surgery

Surgery is not the first-line treatment option for patients with Goodpasture syndrome. Renal transplantation is usually reserved for patients who present with undetectable circulating anti-glomerular basement antibodies in serum for 12 months and atleast 6 months after stopping the use of cytotoxic agents.

Secondary Prevention

Effective measures for the secondary prevention of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys. Patients should be monitored regularly for renal function and those with severe dysfunction should have be referred for dialysis.

References

Template:WH Template:WS